Idiopathic Pulmonary Fibrosis Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

April 13 21:33 2023
Idiopathic Pulmonary Fibrosis Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Idiopathic Pulmonary Fibrosis (IPF) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Some of the key players in the market include FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., and others.

Idiopathic Pulmonary Fibrosis (IPF) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Idiopathic Pulmonary Fibrosis Market. 

The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Idiopathic Pulmonary Fibrosis Pipeline Analysis

Idiopathic Pulmonary Fibrosis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Idiopathic Pulmonary Fibrosis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Idiopathic Pulmonary Fibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Mechanism of Action of the Emerging Pipeline Therapies 

  • Connective tissue growth factor inhibitor

  • Type 4 cyclic nucleotide phosphodiesterase inhibitors

  • Factor XIIa inhibitor

  • PORCN protein inhibitor

  • Galectin 3 inhibitor

  • Integrin alphavbeta1 inhibitor

  • SMO protein inhibitor

  • Caveolin-1 replacement

  • Undefined mechanism

  • CXCR4 receptor antagonist

Learn How the Ongoing Clinical & Commercial Activities will Affect the Idiopathic Pulmonary Fibrosis Therapeutic Segment @

Idiopathic Pulmonary Fibrosis Therapeutics Landscape

There are approx. 80+ key companies developing therapies for Idiopathic Pulmonary Fibrosis. Currently, Hoffmann-La Roche is leading the therapeutics market with its Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market Include:

Algernon Pharmaceuticals, Astra Zeneca, Avalyn Pharmaceuticals, Bellerophon Therapeutics, Boehringer Ingelheim, Bridge Biotherapeutics, Bristol-Myers Squibb, Calliditas Therapeutics, Celgene Pharmaceutical, CSL Behring, Daewoong Pharmaceutical, Endeavor BioMedicines, FibroGen, Galecto Biotech AB, Guangdong Raynovent, Horizon Therapeutics, Insmed, Kadmon Pharmaceuticals, Kinarus AG, Lung Therapeutics, MediciNova, Metagone Biotech, Nitto Denko, Novartis, Pliant Therapeutics, PureTech Health, Regend Therapeutics, Roche, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Syndax Pharmaceuticals, Taiho Pharmaceutical, United Therapeutics, Vicore Pharma, and others.

Idiopathic Pulmonary Fibrosis Emerging and Marketed Drugs Covered in the Report Include:

  • BG-00011: Biogen

  • BMS-986020: Bristol-Myers Squibb

  • CC-90001: Celgene Corporation

  • ESBRIET (Pirfenidone): Hoffmann-La Roche Ltd

  • Gefapixant: Merck & Co., Inc.

  • GLPG4716: Galapagos NV

  • LT-1002: Chong Kun Dang Pharmaceutical

  • OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG

  • Pamrevlumab: FibroGen, Inc.

  • PBI4050: ProMetic Life Sciences

  • PLN-74809: Pliant Therapeutics

  • PRM-151 (RG6354): Hoffmann-La Roche Ltd

  • TAS-115: Taiho Pharmaceutical

  • TD139 (Bristol-Myers Squibb

  • Thrombomodulin Alfa: Asahi Kasei Pharma Corporation

  • Tipelukast: MediciNova

  • Tyvaso (inhaled treprostinil): United Therapeutics

  • VAY-736: MorphoSys; Novartis

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Latest Key Update in the Idiopathic Pulmonary Fibrosis Therapeutics Market 

On April 03, 2023, FibroGen, Inc. (NASDAQ: FGEN) announced the completion of patient enrollment for ZEPHYRUS-2, a Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease.

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Idiopathic Pulmonary Fibrosis Current Treatment Patterns

4. Idiopathic Pulmonary Fibrosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Idiopathic Pulmonary Fibrosis Late Stage Products (Phase-III)

7. Idiopathic Pulmonary Fibrosis Mid-Stage Products (Phase-II)

8. Idiopathic Pulmonary Fibrosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Idiopathic Pulmonary Fibrosis Discontinued Products

13. Idiopathic Pulmonary Fibrosis Product Profiles

14. Key Companies in the Idiopathic Pulmonary Fibrosis Market

15. Key Products in the Idiopathic Pulmonary Fibrosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Idiopathic Pulmonary Fibrosis Unmet Needs

18. Idiopathic Pulmonary Fibrosis Future Perspectives

19. Idiopathic Pulmonary Fibrosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

view more articles

About Article Author